George Gavrila
Baltimore, MDNPI 1861627994
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $223,163 of the $312,389 with a category attached, or 71.4%. AbbVie accounts for 72.5% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $65,194 and has fallen 76.4% since, to $15,414 in 2025.
Across 527 payments — averaging $592.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$226K
- Galderma Laboratories, L.p.$84K
- Revance Therapeutics, Inc.$2K
- Merz North America, Inc.$185
What the payments were for
- Consulting fees$47,36015%
- Speaking & faculty fees$223,16371%
- Travel & lodging$30,70210%
- Food & beverage$11,1444%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 307 | $226,349 |
| Galderma Laboratories, L.p. | 174 | $83,771 |
| Revance Therapeutics, Inc. | 45 | $2,084 |
| Merz North America, Inc. | 1 | $185 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$98,286
- BOTOX COSMETIC$52,018
- KYBELLA$1,950
- DAXXIFY$499
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.